Understanding Tysabri and PML: A Medical Record of Safety

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specific Risk Awareness

If you or a loved one is taking Tysabri, you may have concerns about progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Decades of pharmacovigilance have established a clear understanding of how PML risk correlates with treatment duration and other factors. This page provides a chronological overview of Tysabri's safety profile, including key FDA warnings and monitoring recommendations.

Find Out If You Qualify for Compensation →

Bridging to Tysabri and Progressive Multifocal Leukoencephalopathy

The bridge between general health education and occupational exposure concern is built upon the principle that risk awareness must extend beyond the clinic. When a therapy’s administration or patient management involves repeated contact, the potential for inadvertent exposure becomes a legitimate occupational health consideration. This transition does not assert causal mechanisms but rather acknowledges that the legacy of health information now supports a more focused inquiry into how specific therapeutic contexts intersect with workplace safety and legal accountability. Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus.

Medical Evidence: Tysabri and PML Risk

Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system resulting from reactivation of the JC virus in immunocompromised individuals. Clinical presentation typically includes subacute neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and ataxia. Diagnosis relies on MRI findings of multifocal white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that binds to alpha-4 integrin, inhibiting lymphocyte migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV. The drug's labeling includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The mechanistic pathway linking Tysabri to PML involves reduced trafficking of CD4+ and CD8+ T cells into the brain, which compromises JCV-specific immune control. This allows JCV to replicate in oligodendrocytes, leading to lytic infection and demyelination. The drug's labeling emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing adverse event reports from the FDA FAERS database list fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder among the most frequently reported events, though PML is a specific serious adverse reaction (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Legal Context for Illinois Patients

Risk anchors include the adequacy of warnings provided to patients and healthcare providers. The boxed warning and restricted distribution program (TOUCH) aim to mitigate PML risk through mandatory education and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients who develop PML may face questions about whether they were adequately informed of the risks and whether monitoring protocols were followed. Attorney-related considerations for affected patients include potential claims of failure to warn, inadequate risk communication, or delayed diagnosis. The timeline between Tysabri exposure and PML onset varies; cases have been reported after as few as eight doses or after several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability complicates attribution but underscores the need for vigilant monitoring throughout therapy. For Illinois residents affected by Tysabri-associated PML, legal counsel may evaluate whether prescribing physicians or the manufacturer fulfilled their duty to warn. The boxed warning explicitly states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and risk factors are clearly delineated. Nonetheless, individual cases may involve nuances such as whether anti-JCV antibody testing was performed, whether treatment duration exceeded two years without reassessment, or whether prior immunosuppressant use was considered. The FDA adverse event data provide a broad view of reported harms, but PML-specific reports are not separately quantified in the summary (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). In summary, Tysabri carries a known risk of PML, with established risk factors and a mechanistic basis in immune modulation. Patients and providers must adhere to monitoring protocols. Those who develop PML may have legal recourse if warnings were insufficient or if risk management was inadequate. The evidence underscores the importance of informed consent and ongoing vigilance.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug's boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can Illinois residents affected by Tysabri-associated PML pursue legal action?

Yes, Illinois residents who developed PML after Tysabri use may have legal claims for failure to warn, inadequate risk communication, or delayed diagnosis. An attorney can evaluate whether prescribing physicians or the manufacturer fulfilled their duty to warn based on the boxed warning and monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.